Mackenzie Financial’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $29.6M | Buy |
175,685
+84,008
| +92% | +$12.5M | 0.03% | 354 |
|
|
2026
Q1 | $12.1M | Buy |
91,677
+14,837
| +19% | +$1.97M | 0.01% | 492 |
|
|
2025
Q4 | $10.8M | Sell |
76,840
-8,034
| -9% | -$1.16M | 0.01% | 488 |
|
|
2025
Q3 | $11.9M | Buy |
84,874
+9,157
| +12% | +$1.24M | 0.01% | 470 |
|
|
2025
Q2 | $9.52M | Sell |
75,717
-10,392
| -12% | -$1.19M | 0.01% | 490 |
|
|
2025
Q1 | $9.52M | Buy |
86,109
+30,888
| +56% | +$3.91M | 0.01% | 469 |
|
|
2024
Q4 | $7.54M | Sell |
55,221
-31,362
| -36% | -$3.88M | 0.01% | 510 |
|
|
2024
Q3 | $9.98M | Sell |
86,583
-2,244
| -3% | -$308K | 0.01% | 442 |
|
|
2024
Q2 | $12.2M | Sell |
88,827
-2,983
| -3% | -$409K | 0.02% | 404 |
|
|
2024
Q1 | $12.7M | Sell |
91,810
-5,045
| -5% | -$689K | 0.02% | 400 |
|
|
2023
Q4 | $12.8M | Buy |
96,855
+1,224
| +1% | +$141K | 0.02% | 404 |
|
|
2023
Q3 | $10.6M | Buy |
95,631
+3,277
| +4% | +$345K | 0.02% | 422 |
|
|
2023
Q2 | $8.73M | Buy |
92,354
+44,056
| +91% | +$4.3M | 0.01% | 471 |
|
|
2023
Q1 | $4.89M | Buy |
48,298
+8,829
| +22% | +$919K | 0.01% | 558 |
|
|
2022
Q4 | $4.71M | Buy |
39,469
+4,006
| +11% | +$469K | 0.01% | 528 |
|
|
2022
Q3 | $3.77M | Sell |
35,463
-7,673
| -18% | -$779K | 0.01% | 570 |
|
|
2022
Q2 | $4.21M | Buy |
43,136
+13,240
| +44% | +$1.22M | 0.01% | 567 |
|
|
2022
Q1 | $2.8M | Buy |
29,896
+19,703
| +193% | +$1.67M | ﹤0.01% | 689 |
|
|
2021
Q4 | $868K | Sell |
10,193
-4,533
| -31% | -$417K | ﹤0.01% | 932 |
|
|
2021
Q3 | $1.41M | Buy |
14,726
+5,017
| +52% | +$474K | ﹤0.01% | 826 |
|
|
2021
Q2 | $945K | Sell |
9,709
-136
| -1% | -$13K | ﹤0.01% | 885 |
|
|
2021
Q1 | $957K | Sell |
9,845
-7,318
| -43% | -$767K | ﹤0.01% | 820 |
|
|
2020
Q4 | $1.65M | Buy |
17,163
+785
| +5% | +$75.8K | ﹤0.01% | 639 |
|
|
2020
Q3 | $1.57M | Buy |
16,378
+8,044
| +97% | +$930K | ﹤0.01% | 598 |
|
|
2020
Q2 | $1.02M | Buy |
8,334
+799
| +11% | +$88.3K | ﹤0.01% | 668 |
|
|
2020
Q1 | $652K | Sell |
7,535
-46
| -0.6% | -$4.5K | ﹤0.01% | 756 |
|
|
2019
Q4 | $815K | Sell |
7,581
-1,241
| -14% | -$130K | ﹤0.01% | 773 |
|
|
2019
Q3 | $795K | Buy |
8,822
+1,572
| +22% | +$147K | ﹤0.01% | 760 |
|
|
2019
Q2 | $612K | Sell |
7,250
-1,444
| -17% | -$119K | ﹤0.01% | 828 |
|
|
2019
Q1 | $766K | Buy |
8,694
+1,225
| +16% | +$102K | ﹤0.01% | 966 |
|
|
2018
Q4 | $533K | Buy |
7,469
+1,684
| +29% | +$161K | ﹤0.01% | 929 |
|
|
2018
Q3 | $711K | Buy |
5,785
+2,951
| +104% | +$335K | ﹤0.01% | 819 |
|
|
2018
Q2 | $278K | Sell |
2,834
-722
| -20% | -$64.6K | ﹤0.01% | 907 |
|
|
2018
Q1 | $295K | Buy |
+3,556
| New | +$300K | ﹤0.01% | 814 |
|
Other funds holding NBIX
Mackenzie Financial's NBIX Position: Q2 2026 in Review
Mackenzie Financial increased its Neurocrine Biosciences (NBIX) stake by 92% in Q2 2026, buying an estimated $12.5M and bringing the position to 175,685 shares worth $29.6M. The position accounts for 0.03% of the portfolio, ranked #354.
Mackenzie Financial first reported a position in NBIX in Q1 2018 and has held it in 34 quarters since. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- Mackenzie Financial held 175,685 shares of Neurocrine Biosciences worth $29.6M as of Q2 2026.
- Mackenzie Financial bought 84,008 Neurocrine Biosciences shares in Q2 2026, an estimated $12.5M.
- Neurocrine Biosciences made up 0.03% of Mackenzie Financial's portfolio in Q2 2026, its #354 holding.
- Mackenzie Financial first reported a position in Neurocrine Biosciences in Q1 2018 and has held it in 34 quarters since.
- 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on Mackenzie Financial's 13F filing for Q2 2026, filed 13 Aug 2026.